Neeta Dhar Grover
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Neeta Dhar Grover has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
DilipV Gokhale
Department of Pharmacology, Bharati Vidyapeeth Deemed University Medical College, Sangli, Maharashtra, India
1 shared publicationRamachandraP Limaye
Department of Pharmacology, Bharati Vidyapeeth Deemed University Medical College, Sangli, Maharashtra, India
1 shared publicationTatyasahebR Patil
Department of Pharmacology, Bharati Vidyapeeth Deemed University Medical College, Sangli, Maharashtra, India
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 45 (6) , 547-55
Zonisamide: A review of the clinical and experimental evidence for its use in Parkinson′s disease
The Indian Journal of Pharmacology is an official organ of the Indian Pharmacological Society
- 1 January 2013
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 45 (6) , 547-55
Open AccessZonisamide: A review of the clinical and experimental evidence for its use in Parkinson′s disease
The Indian Journal of Pharmacology is an official organ of the Indian Pharmacological Society
- Open Access
- 1 January 2013
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 45 (2) , 207-8
Fair or foul?
The Indian Journal of Pharmacology is an official organ of the Indian Pharmacological Society
- 1 January 2013
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 45 (2) , 207-8
Open AccessFair or foul?
The Indian Journal of Pharmacology is an official organ of the Indian Pharmacological Society
- Open Access
- 1 January 2010
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 42 (6) , 422
Echinocandins: A ray of hope in antifungal drug therapy
The Indian Journal of Pharmacology is an official organ of the Indian Pharmacological Society
- 1 January 2010
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 42 (6) , 422
Open AccessEchinocandins: A ray of hope in antifungal drug therapy
The Indian Journal of Pharmacology is an official organ of the Indian Pharmacological Society
- Open Access
- 1 January 2010
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 42 (1) , 9-11
Echinocandins: A ray of hope in antifungal drug therapy
Invasive fungal infections are on the rise. Amphotericin B and azole antifungals have been the mainstay of antifungal therapy so far. The high incidence of infusion related toxicity and nephrotoxicity with amphotericin B and the emergence of fluconazole resistant strains of Candida glabrata egged on the search for alternatives. Echinocandins are a new class of antifungal drugs that act by inhibition of β (1, 3)-D- glucan synthase, a key enzyme necessary for integrity of the fungal cell wall. Caspofungin was the first drug in this class to be approved. It is indicated for esophageal candidiasis, candidemia, invasive candidiasis, empirical therapy in febrile neutropenia and invasive aspergillosis. Response rates are comparable to those of amphotericin B and fluconazole. Micafungin is presently approved for esophageal candidiasis, for prophylaxis of candida infections in patients undergoing hematopoietic stem cell transplant (HSCT) and in disseminated candidiasis and candidemia. The currently approved indications for anidulafungin are esophageal candidiasis, candidemia and invasive candidiasis. The incidence of infusion related adverse effects and nephrotoxicity is much lower than with amphotericin B. The main adverse effect is hepatotoxicity and derangement of serum transaminases. Liver function may need to be monitored. They are, however, safer in renal impairment. Even though a better pharmacoeconomical choice than amphotericin B, the higher cost of these drugs in comparison to azole antifungals is likely to limit their use to azole resistant cases of candidial infections and as salvage therapy in invasive aspergillosis rather than as first line drugs.
- 1 January 2010
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 42 (1) , 9-11
Open AccessEchinocandins: A ray of hope in antifungal drug therapy
Invasive fungal infections are on the rise. Amphotericin B and azole antifungals have been the mainstay of antifungal therapy so far. The high incidence of infusion related toxicity and nephrotoxicity with amphotericin B and the emergence of fluconazole resistant strains of Candida glabrata egged on the search for alternatives. Echinocandins are a new class of antifungal drugs that act by inhibition of β (1, 3)-D- glucan synthase, a key enzyme necessary for integrity of the fungal cell wall. Caspofungin was the first drug in this class to be approved. It is indicated for esophageal candidiasis, candidemia, invasive candidiasis, empirical therapy in febrile neutropenia and invasive aspergillosis. Response rates are comparable to those of amphotericin B and fluconazole. Micafungin is presently approved for esophageal candidiasis, for prophylaxis of candida infections in patients undergoing hematopoietic stem cell transplant (HSCT) and in disseminated candidiasis and candidemia. The currently approved indications for anidulafungin are esophageal candidiasis, candidemia and invasive candidiasis. The incidence of infusion related adverse effects and nephrotoxicity is much lower than with amphotericin B. The main adverse effect is hepatotoxicity and derangement of serum transaminases. Liver function may need to be monitored. They are, however, safer in renal impairment. Even though a better pharmacoeconomical choice than amphotericin B, the higher cost of these drugs in comparison to azole antifungals is likely to limit their use to azole resistant cases of candidial infections and as salvage therapy in invasive aspergillosis rather than as first line drugs.